SR9009 (Stenabolic) Research Overview (also known as Stenabolic, SR9009)
SR9009, commonly called Stenabolic, is a synthetic agonist of the nuclear receptors REV-ERBα and REV-ERBβ, which participate in circadian-clock regulation and metabolic gene expression. It is not a selective androgen receptor modulator (SARM), despite frequently being marketed alongside SARMs, and it remains an experimental research compound without established human efficacy, dosing, or long-term safety data.
What Is SR9009?
SR9009, also known as Stenabolic, is a synthetic small-molecule agonist developed in work associated with Professor Thomas Burris at the Scripps Research Institute. It was designed to activate REV-ERB nuclear receptors, especially REV-ERBα and REV-ERBβ, sometimes written as Rev-ErbA and Rev-ErbB. These receptors are components of the molecular machinery that links the circadian clock with metabolism. Early laboratory studies reported that pharmacological activation of REV-ERB altered the expression of clock-related genes, increased energy expenditure, promoted fatty-acid oxidation, and changed metabolic physiology in mice. Those findings generated interest in obesity, metabolic syndrome, endurance, mitochondrial biology, and circadian-rhythm research.
SR9009 is not a SARM. SARMs act primarily at the androgen receptor, whereas SR9009 is intended to modulate transcription through REV-ERB receptors. The two categories are frequently grouped together by online vendors and performance-drug communities, but that classification is pharmacologically inaccurate. In mouse experiments, SR9009 was associated with changes in mitochondrial number and function and with increased fat oxidation, but these effects should not be interpreted as proven human effects. A major unresolved issue is oral bioavailability: much of the foundational animal work used subcutaneous administration, while many products marketed to people are oral preparations with uncertain absorption and identity. Public sources often describe an approximately four-hour half-life, although reliable human pharmacokinetic data are lacking. This has led to proposed multiple-daily dosing schedules, but no clinically validated schedule exists. SR9009 remains a research-only compound, and it has not been approved as a medicine or dietary supplement.
Research Indications
Circadian Rhythm & Metabolism
REV-ERB receptor activation
SR9009 is a synthetic agonist of REV-ERBα and REV-ERBβ, nuclear receptors that participate in circadian transcriptional regulation and metabolic gene expression.
Metabolic gene programs
Rodent and cellular studies report altered expression of genes involved in lipid handling, glucose metabolism, and energy expenditure following pharmacologic REV-ERB activation.
Exercise Capacity & Skeletal Muscle
Endurance-related effects in animals
Preclinical experiments reported increased oxidative capacity and improved exercise-related measures in mice. These findings have not established efficacy or safety in humans.
Mitochondrial and autophagy signaling
REV-ERBα research links receptor signaling with skeletal-muscle mitochondrial biogenesis, oxidative metabolism, and autophagy pathways in model systems.
Inflammation & Disease Models
Inflammatory signaling models
REV-ERB pathways are being investigated in immune and inflammatory biology; results from animal and in vitro disease models remain exploratory.
Translational limitations
SR9009 is not an approved medicine, and controlled human clinical data sufficient to support therapeutic indications are lacking.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Human clinical use | No established dose | Not established | Oral |
| Preclinical circadian studies | Typically reported as animal mg/kg dosing | Study-specific | Oral |
| Exercise-model research | No validated human translation | Not established | Oral |
| Research-community protocols | Variable; not clinically validated | Variable | Oral |
Timing
REV-ERB signaling is circadian. In animal studies, effects can depend on dosing time relative to the light-dark cycle; there is no established human timing regimen. Avoid treating preclinical schedules as human-use guidance.
Peptide Interactions
Human safety data are absent; alcohol may compound uncertainty around hepatic, metabolic, sleep, and circadian effects.
Potential sleep disruption, cardiovascular symptoms, and circadian disturbance may make combined use difficult to assess.
REV-ERB biology affects metabolic pathways; people using insulin or other glucose-lowering therapy should not self-experiment without clinician oversight.
There are insufficient clinical interaction data; do not assume lack of a reported interaction means compatibility with prescription therapy.
Developmental and reproductive safety have not been established; use should be avoided.
Reported Research Timeline
01Hours to days (reported in cited studies): no reliably characterized acute effects in humans. Subjective reports are not a substitute for controlled pharmacokinetic or safety data.
02Days 1–7 (reported in cited studies): circadian factors such as sleep timing, light exposure, diet, and training can strongly confound perceived changes in energy or performance.
03Weeks 1–2 (reported in cited studies): animal studies suggest transcriptional and metabolic effects may develop with repeated exposure, but no comparable human response timeline is validated.
04Weeks 3–4 (reported in cited studies): claimed endurance or body-composition changes remain unproven in humans and may reflect changes in diet, training volume, sleep, or product composition.
05Weeks 4–8 (reported in cited studies): longer exposure increases uncertainty because formal human toxicology, interaction, and long-term outcome data are not available.
06After discontinuation (reported in cited studies): there is no established human washout period or evidence-based monitoring schedule; seek clinical advice if symptoms or abnormal laboratory findings occur.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
SR9009 is an investigational research chemical, not an approved SARM or approved therapeutic drug.
Human pharmacokinetics, effective dosing, adverse-event rates, and long-term safety are not adequately established.
Avoid use with pregnancy, breastfeeding, active liver disease, significant cardiovascular disease, or uncontrolled metabolic disease.
Products sold as SR9009 may be mislabeled, underdosed, overdosed, or contaminated; oral capsules and powders require particular attention to identity and dose verification.
SR9009 and related agents may be prohibited in sport under anti-doping rules; athletes should verify current regulations before any exposure.
Seek Medical Attention If:
You develop chest pain, fainting, severe shortness of breath, a persistent rapid heartbeat, or new neurologic symptoms.
You experience facial swelling, wheezing, widespread rash, or other signs of a serious allergic reaction.
You have jaundice, dark urine, severe abdominal pain, persistent vomiting, or marked unexplained fatigue.
You develop severe agitation, confusion, major sleep disruption, or thoughts of self-harm.
Quality Indicators
Verified Marker
Lot-specific third-party COA
A current certificate of analysis should identify the exact lot, testing laboratory, sample date, and tested material.
Verified Marker
Identity confirmation by LC-MS or NMR
A credible report should confirm compound identity with an orthogonal analytical method, not only a vendor-generated chromatogram.
Verified Marker
Quantitative HPLC purity result
Look for a dated HPLC or UPLC assay showing stated purity, chromatogram conditions, and disclosed unidentified peaks.
Acceptable Range
Capsule or powder mass verification
For oral products, label mg accuracy should be supported by content-uniformity or quantitative assay data for the finished dosage form.
Quality Concern
Undated, generic, or mismatched documentation
Avoid products with recycled COAs, no lot matching, implausible purity claims, missing laboratory details, or no testing for contaminants.
Research Citations
- Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists
Solt, L. A., Wang, Y., Banerjee, S., et al., 2012, Nature - Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy
Woldt, E., Sebti, Y., Solt, L. A., et al., 2013, Nature Medicine - The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator
Preitner, N., Damiola, F., Lopez-Molina, L., et al., 2002, Cell - REV-ERBα, a component of the circadian clock, negatively regulates the inflammatory response
Gibbs, J. E., Blaikley, J., Beesley, S., et al., 2009, Nature Medicine - Rev-erbα and Rev-erbβ coordinately protect the circadian clock and normal metabolic function
Cho, H., Zhao, X., Hatori, M., et al., 2012, Cell
Research Focus
circadian rhythm, Rev-ErbA, fat oxidation, endurance, metabolic health, mitochondrial biogenesis
Frequently Asked Questions
What should researchers watch for with SR9009 (Stenabolic)?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with SR9009 (Stenabolic)?
Hours to days (reported in cited studies): no reliably characterized acute effects in humans. Subjective reports are not a substitute for controlled pharmacokinetic or safety data.
How is SR9009 (Stenabolic) typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →